Charles A. Blake

Expression of the GATA-4 and GATA-6 transcription factors in the fetal rat gonad and in the ovary during postnatal development and pregnancy

Immunohistochemical studies were undertaken to determine the distribution of GATA-4 and GATA-6 in rat fetal gonad and the postnatal ovary during development and pregnancy. In the undifferentiated gonad, GATA-4 was expressed in the somatic cells of both sexes. After differentiation of the ovary and testis, GATA-4 expression continued in both ovarian and testicular somatic cells; whereas, GATA-6 was expressed in both somatic and germ cells. In the ovary of postnatal rats, granulosa and thecal cells of healthy follicles expressed both GATA factors. In the adult rat, GATA-4 expression was lower in corpora lutea as compared to follicles; whereas, GATA-6 was strongly expressed in both structures. GATA-4 expression was greater in functional corpora lutea than regressing corpora lutea. GATA-6 was expressed in both functional and regressing corpora lutea. In all postnatal ovaries, the expression of P450scc localized with tissue expressing GATA-4 and/or GATA-6, but GATA expression also occurred in P450scc negative cells.

Monosodium Glutamate Disruption of Behavioral and Endocrine Function in the Female Rat

Experiments were conducted to determine the effects of neonatal administration of L-monosodium glutamate (MSG) on behavioral and endocrine function in the female rat. Administration of MSG (4 mg/kg body weight) at days 1, 3, 5, 7 and 9 in neonates results in a delay of vaginal opening (VO) and the absence of ovulation at the time of VO. However, some rats were observed to ovulate after VO if they were subjected to sequential laparotomies. MSG-treated rats also fail to exhibit compensatory ovarian hypertrophy. Ovariectomized MSG-treated rats injected with estradiol benzoate (EB) followed by a progesterone injected 2 days later did not exhibit sexual beahvior to male rats, while all the control rats displayed lordosis. Chronic treatment with EB for 12 days, followed by a progesterone injection on the 12th day, resulted in a marked improvement of the sexual receptivity of the MSG-treated rats. The body weight of the MSG-treated animals was lower than that of the controls during development although the MSG animals looked obese. Food intake is normal in the MSG-treated rats, but when expressed as intake/100 g body weight, the MSG-treated rats appeared slightly hyperphagic, MSG-treated rats respond with increased food intake after ovariectomy and EB treatment suppresses the increased food intake. Thus, the control of food intake by estrogen does not seem to be affected by the MSG treatment; in fact, these animals seem to be more sensitive than control rats to the anorectic effects of EB. Neonatal MSG treatment appears to affect the neural control for the tonic secretion of gonadotropins by destroying arcuate nuclei. This undoubtedly reduces the reproductive capacity of the animals by impeding the growth and secretions of their ovaries. The findings that chronic estrogen followed by progesterone treatment can reinstate sexual receptivity in MSG-treated animals suggests that the arcuate nuclei are not needed for the expression of sexual behavior and that estrogens might remedy the fertility problems of MSG-treated animals.

Serum Testosterone Concentrations during the 4-Day Estrous Cycle in Normal and Adrenalectomized Rats

Abstract We investigated the role of the adrenal glands in the maintenance of serum testosterone concentrations during the 4-day estrous cycle in the rat. Animals were untreated, adrenalectomized (ADX), or sham-ADX. The operations did not alter with the length of the estrous cycle. Three to five estrous cycles after surgery, we decapitated rats for the collection of trunk blood and measured the FSH, LH, and testosterone in the serum by radioimmunoassays. Serum FSH and LH concentrations were similar in the three groups of rats during the estrous cycle except at 1000 hr of estrus when serum FSH levels were lower in the untreated rats than in the other two groups. In untreated rats, serum testosterone concentrations were lowest during estrus and highest after the onset of the preovulatory surges of FSH and LH in serum during the afternoon of proestrus. No significant differences in serum testosterone concentrations were observed between groups except that levels in the ADX rats were lower than levels in the untreated rats at 1000 and 1800 hr of diestrous day 1, and levels in the ADX rats were lower than levels in the sham-ADX rats at 0600 hr of estrus. Serum testosterone levels were undetectable in rats ovariectomized and adrenalectomized for 2 weeks. The results indicate that the adrenal glands contribute little to the maintenance of serum testosterone levels during the rat 4-day estrous cycle and that the rise in serum testosterone concentration from estrus to the afternoon of proestrus is likely the result of ovarian secretions.

Effects of neuropeptide Y on LH, FSH and TSH release in male rats

These experiments were undertaken to investigate the effects of systemically administered neuropeptide Y (NPY) on gonadotropin secretion in the intact male rat and to determine whether the effects observed might be mediated by a direct action of NPY alone on the anterior pituitary gland (APG). Subcutaneous administration of 10 micrograms of NPY caused a greater than 2-fold increase in serum luteinizing hormone (LH) concentration at 15 min after injection but was without effect on serum follicle-stimulating hormone (FSH) or thyrotropin-stimulating hormone (TSH) levels. The addition of NPY (final concentrations of 10(-8) to 10(-11) M) or the structurally similar neuropeptide, rat pancreatic polypeptide, to culture medium containing hemi-APG did not alter the release of LH, FSH, or TSH. The results indicate that systemically administered NPY can elevate serum LH concentration in intact male rats. This effect does not appear to be due to NPY acting alone at the level of the APG.

Restoration of the periovulatory follicle-stimulating hormone surges in sera by luteinizing hormone releasing hormone in phenobarbital-blocked rats.

Abstract The periovulatory increases of follicle-stimulating hormone (FSH) in rat sera can be divided into two phases. The first phase consists of a rise and fall during proestrus and the second phase consists of a rise and fall during estrus. The second phase was not blocked by phenobarbital (100 mg/kg BW) injected i.p. between the first and second phases. In contrast, phenobarbital administered prior to the onset of the first phase blocked both phases of increased serum FSH. In phenobarbital-blocked rats, administration of luteinizing hormone releasing hormone (LHRH) during proestrus, either by s.c. injection (10 μg) or by a 3 hr constant-rate i.v. infusion (50 ng/hr), simulated both the proestrous and estrous phases of increased serum FSH. These results indicate that 1) the second phase of the serum FSH rise is itself not susceptible to phenobarbital blockade, 2) a proestrous mechanism susceptible to phenobarbital alteration is necessary for both phases of increased serum FSH to occur, and 3) administration of LHRH to phenobarbital-blocked rats during proestrus restores both phases of FSH release.

Perinatal exposure to low-dose DE-71 increases serum thyroid hormones and gonadal osteopontin gene expression.

Polybrominated diphenyl ethers (PBDEs) are flame retardants that have been widely used in manufacturing. They are major household and environmental contaminants that bioaccumulate. Humans are exposed primarily through dust inhalation and dietary ingestion of animal products. In animal studies, high doses of penta-brominated diphenyl ethers (penta-BDEs) in the mg/kg body weight (BW) range negatively impact brain development, behavior, memory, circulating thyroid hormone concentrations, the reproductive system and bone development. We investigated the effects of ingestion of a relatively low dose of the penta-BDE mixture DE-71 by pregnant and lactating rats on reproductive and thyroid parameters of the F1 offspring. F0 mothers received 60 μg/kg BW of DE-71 or vehicle daily by gavage from Day 1.5 of pregnancy through lactation (except the day of parturition). F1 pups were sacrificed at 21 d of age or outbred at approximately 80 d of age. Bred F1 females were sacrificed at Day 14.5 of pregnancy or at five months of age. Bred F1 males were sacrificed at five months of age. DE-71 treatment of the mothers affected the F1 females as evidenced by lower body weights at 80 d and five months of age, elevated serum T3 and T4 concentrations at Day 14.5 of pregnancy and increased thyroid gland weight and ovarian osteopontin mRNA at five months of age. Perinatal DE-71 exposure also increased testicular osteopontin mRNA in 21-day-old F1 males. Utilizing a granulosa cell in vitro model, we demonstrated that DE-71 activated the rat osteopontin gene promoter. Our results are the first to demonstrate that PBDEs increase rodent circulating T3 and T4 concentrations and gonadal osteopontin mRNA, and activate the osteopontin gene promoter. These changes may have clinical implications as others have shown associations between human exposure to PBDEs and subclinical hyperthyroidism, and overexpression of ovarian osteopontin has been associated with ovarian cancer.

Estrogen can protect splenocytes from the toxic effects of the environmental pollutant 4-tert-octylphenol

Four-tert-octylphenol (OP), an environmental pollutant, exerts apoptotic effects on cultured mouse splenocytes. Although OP binds to estrogen receptors, these apoptotic effects are not exerted by 17β-estradiol (E). It remained possible that OP might bind to estrogen receptors and subsequently exert apoptotic effects not exerted by E after it binds to the same receptors. It also remained possible that E-primed splenocytes might respond to OP differently than splenocytes not exposed to E. Thus, we investigated OP and E interactions on the viability of mouse splenocytes in culture. The total number of splenocytes (cells stained and not stained with trypan blue) was not altered or altered slightly after incubation with any agent for 24 h. Incubation of splenocytes in medium containing 5×10−5 or 5×10−7M OP decreased the percentage of viable cells by approx 47% and 25%, respectively. The addition of 0.8×10−5 to 0.8×10−9M E to cultures was without effect or decreased the percentage of viable cells by only approx 5%. The addition of these concentrations of E simultaneously with or at 2 h after the addition of 5×10−5M or 5×10−7M OP to cultures did not interfere with the OP-induced decreases in cell viability. By contrast, incubation of splenocytes in medium containing E for 2 h prior to the subsequent addition of either dose of OP blocked the OP-induced decreases in cell viability in a dose-response manner. There was a marked reduction in the percentage of viable cells (70%) when splenocytes were incubated with 0.5×10−5M dexamethasone. The addition of 0.8×10−5M E at 2 h prior to the addition of dexamethasone did not prevent the decreased cell viability. Incubation of cells in medium with 0.8×10−5M testosterone caused a small decrease in splenocyte viability similar to that observed with E. However, unlike E, the addition of testosterone at 2 h prior to the addition of 5×10−5M OP did not prevent the OP-induced decrease in cell viability. These data suggest the presence of estrogen receptors in some splenocytes. They also suggest that if OP binds to these estrogen receptors or other receptors in the absence or initial presence of E, the resulting effect is toxic to the cells. By contrast, exposure of splenocytes to E prior to their exposure to OP can prevent the toxicity of OP.

A decrease of cytosol estrogen receptors in the hypothalamus as a result of treatment of neonatal rats with glutamate

SummaryExperiments were performed to determine whether the neuroendocrine dysfunctions of rats treated neonatally with monosodium glutamate (MSG) could be related to a loss of cytoplasmic estrogen receptors. Female rats treated with MSG as neonates were ovariectomized as adults and killed by decapitation 2 or 3 weeks after ovariectomy. Body, gonadal and anterior pituitary gland weights in MSG-treated rats were depressed when compared to that seen in their littermate controls. Serum prolactin concentration was elevated in the MSG-treated rats. Serum luteinizing hormone (LH) concentration was significantly lower in MSG-treated rats than in controls at 2 weeks, but not at 3 weeks after ovariectomy, suggesting a sluggish postovariectomy rise of serum LH concentration. Serum follicle-stimulating hormone (FSH) concentration was not altered by the MSG treatment. The concentration of cytosol estrogen receptors in the anterior pituitary gland was similar to that of controls, but hypothalamic concentration of estrogen receptors decreased as a result of the MSG treatment. After dissection of different hypothalamic regions, it was found that the greatest depletion of the cytosol estrogen receptors occurred in the arcuate-median eminence region. The results raise the possibility that some reproductive impairments of MSG-treated rats could stem from a decrease in cytosol estrogen receptors in the arcuatemedian eminence region.

A change in basal FSH release accompanies the onset of the second or selective phase of increased serum FSH in the cyclic rat

Abstract Experiments were undertaken to investigate if changes occur at the level of the anterior pituitary gland to result in selective follicle-stimulating hormone (FSH) release during late proestrus in the cyclic rat. At 1200 h proestrus, prior to the preovulatory luteinizing hormone (LH) surge in serum and the accompanying first phase of FSH release, serum LH and FSH concentrations were low. At 2400 h proestrus, after the LH surge and shortly after the onset of the second or selective phase of FSH release, serum LH was low, serum FSH was elevated about 4-fold, pituitary LH concentration was decreased about one-half and pituitary FSH concentration was not significantly decreased. During a two hour in vitro incubation, pituitaries collected at 2400 h released nearly two-thirds less LH and 2.5 times more FSH than did pituitaries collected at 1200 h. Addition of luteinizing hormone releasing hormone (LHRH) to the incubations caused increased pituitary LH and FSH release. However, the LH and FSH increments due to LHRH in the 2400 h pituitaries were not different from those in the 1200 h pituitaries. The results indicate that a change occurs in the rat anterior pituitary gland during the period of the LH surge and first phase of FSH release which results in a selective increase in the basal FSH secretory rate. It is suggested that this change is primarily responsible for the selective increase in serum FSH which occurs during the second phase of FSH release.

Pituitary refractoriness to luteinizing hormone releasing hormone: its importance in ending the luteinizing hormone surge in the cyclic rat.

Abstract A study was conducted to assess the importance of pituitary refractoriness to luteinizing hormone releasing hormone (LHRH) in ending the preovulatory surge of luteinizing hormone (LH) and in modulating the associated surge of follicle-stimulating hormone (FSH) in rat plasma. Phenobarbital-blocked proestrous rats were infused iv with LHRH at a constant rate of 50 ng/hr to restore the rising and plateau phases of the spontaneous surges of LH and FSH in plasma. Refractoriness to LHRH was demonstrated for LH but not FSH release when LHRH was infused beyond 2 hr. The plasma LH declined from high levels from 2 to 4.5 hr of infusion while the plasma FSH remained at an elevated plateau. The decline in plasma LH was not as rapid as that observed when the infusion was ended. Injection of a large dose (1 μg) of LHRH at 2 or 3.5 hr after the start of infusion caused substantial increases in plasma LH and FSH but only the LH response after the later injection was less than that observed in other rats given the injection earlier. The results suggest that pituitary refractoriness to LHRH plays a minor role in expediting the decline in the plasma LH during the latter portion of the LH surge and that it has no appreciable effect on the pattern of the plasma FSH at this time.